Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H2Mab-41 Exerts Antitumor Activity in a Mouse Xenograft Model of Colon Cancer

Yukinari Kato, Tomokazu Ohishi, Shinji Yamada, Shunsuke Itai, Junko Takei, Masato Sano, Takuro Nakamura, Hiroyuki Harada, Manabu Kawada, Mika K. Kaneko

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)


The expression of human epidermal growth factor receptor 2 (HER2) has been reported to be overexpressed in several cancers, such as breast, lung, gastric, pancreatic, and colorectal cancers, and be associated with poor clinical outcomes. Trastuzumab, a humanized anti-HER2 antibody, provides significant survival benefits for patients with HER2-overexpressing breast cancers and gastric cancers. In this study, we developed a novel anti-HER2 monoclonal antibody (mAb), H2Mab-41 (IgG2b, kappa), and the antitumor activity of H2Mab-41 was investigated using mouse xenograft models. Caco-2 cells (human colon cancer cell line), which expresses HER2, were subcutaneously implanted into the flanks of nude mice. H2Mab-41 and control mouse IgG were injected three times into the peritoneal cavity of mice. H2Mab-41 significantly reduced tumor development of Caco-2 xenograft in comparison with the control mouse IgG on days 5, 8, 11, 15, and 19. Taken together, these results suggest that H2Mab-41 is useful for antibody therapy against HER2-expressing colon cancers.

Original languageEnglish
Pages (from-to)157-161
Number of pages5
JournalMonoclonal antibodies in immunodiagnosis and immunotherapy
Issue number4
Publication statusPublished - 2019 Aug


  • HER2
  • antitumor activity
  • colon cancer
  • monoclonal antibody

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Anti-Human Epidermal Growth Factor Receptor 2 Monoclonal Antibody H<sub>2</sub>Mab-41 Exerts Antitumor Activity in a Mouse Xenograft Model of Colon Cancer'. Together they form a unique fingerprint.

Cite this